Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
ING says the US dollar has lost a portion of its safe-haven appeal since 2024, while overall demand for the currency has not broadly deteriorated. The dollar index fell almost 10% last year in its weakest annual showing since 2017. ING highlights cyclical drivers of recent weakness, continued holdings by private investors, and no current signs of a…
Director Raymond Debbane purchased 150,000 shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) in two transactions on February 19-20, 2026. The buying occurred as the stock has risen 107% over the past year and follows a financing package of roughly $100 million. The FDA has cleared Lexicon's pilavapadin to advance to two Phase 3, placebo-controlled, …
Gilead Sciences agreed to acquire Arcellx for up to $7.8 billion in cash, paying $115 per share - a 79% premium to Arcellx's last close - to strengthen its cancer-treatment offerings. The deal links Gilead, through its Kite Pharma unit, to the development of anito-cel, an investigational CAR-T therapy for multiple myeloma that is under FDA review w…
Wolfe Research increased its price target for Alliant Energy to $78 from $76 and kept an Outperform rating after the utility reported results broadly in line with expectations and reaffirmed 2026 guidance. Management also maintained a 2027-2029 EPS compound annual growth rate above 7%, and the company is pursuing additional load that could add 2 to…
Deutsche Bank raised price targets across several Spanish banks and upgraded ratings for Bankinter, Banco Sabadell and CaixaBank after analysts observed stronger-than-expected net interest income resilience in 2025, diversified fee income and tighter cost control. The bank expects net interest income to resume growth in 2026 and projects returns on…
Celsius Holdings shares climbed after management disclosed larger-than-expected shelf space increases for both Alani Nu and the Celsius brand at a recent investor conference. TD Cowen reiterated a Buy rating and highlighted the quantified distribution gains, while projecting above-consensus sales and EBITDA for coming years.
Evercore ISI says the recent, indiscriminate selloff of AI-exposed stocks has opened chances to pick firms with resilient strategies. The firm argues that companies investing early in orchestration, secure enterprise guardrails and agentic execution across siloed data will be best placed as AI adoption broadens, and it names eight stocks it views a…
Goldman Sachs reiterated its Buy rating and $600.00 price target on Microsoft following the company’s announcement of the Maia 200 AI inference accelerator. The firm highlighted progress in Microsoft’s internal silicon effort and noted that early Maia disclosures point to compute performance more comparable with competitors. Analysts see significan…
Raymond James reiterated a Strong Buy rating for Palvella Therapeutics (PVLA) with a $193 price target, joining other analysts who maintain a Strong Buy consensus. Palvella raised its internal efficacy threshold for a decisive outcome in its Phase 3 MLM program to a mean mLM-IGA of at least +1.0, with an upside case of at least +1.5. The stock has …
Deutsche Bank downgraded Harmony Biosciences from Buy to Hold and reduced its price objective to $31 from $47 following a Delaware bench trial that appeared to favor a generic challenger. The ruling introduces heightened uncertainty around the exclusivity period for WAKIX and coincides with company-reported 2025 product sales and 2026 guidance that…
Deutsche Bank has begun coverage of Ethos Technologies (LIFE) with a Buy rating and a $23 price target, using a 2027 EV/EBITDA multiple to value the business. The bank highlights Ethos's asset-light approach, technology stack and multi-channel distribution as drivers of market share gains, while forecasting strong policy, revenue and adjusted EBITD…
Williams Trading kept a Hold rating and a $17.00 price target on Wolverine World Wide (NYSE: WWW), cutting revenue forecasts because of anticipated weakness in the Saucony brand even as other brands show mixed trends. The stock is trading slightly above the analyst target and InvestingPro's Fair Value estimate as the company approaches its fourth-q…
Mizuho increased its price target for Consolidated Edison to $118 from $112 and retained an Outperform rating after the utility reported stronger-than-expected 2025 results and provided 2026 guidance. Regulators approved a three-year electric and gas rate plan, the company trimmed its equity issuance expectations, and management outlined multi-year…
Mizuho boosted its price target for Enlight Renewable Energy (ENLT) from $27 to $37 while leaving its Underperform rating intact. The bank's higher target reflects expected higher run-rate revenues by the end of 2028 tied to portfolio growth, acquisitions and improved capital access through private placements. Despite operational progress and strat…
Mizuho increased its 12-month price target for Alliant Energy to $73 from $70 but left its rating at Neutral. The utility posted 2025 EPS slightly above consensus, affirmed 2026 guidance and long-term growth targets, and outlined a multi-gigawatt project pipeline even as costs and regulatory activity create near-term headwinds.
Mizuho increased its 12-month price target for Evergy Inc. (NASDAQ: EVRG) to $82 from $76 while retaining a Neutral rating. The broker pointed to signed data center agreements and a larger five-year capital program as drivers for its outlook, but flagged weak credit metrics amid a significant capital expenditure cycle as the reason it did not upgra…
Mizuho increased its 12-month price target on CenterPoint Energy to $44 from $42 while maintaining a Neutral rating following the utility's in-line fourth-quarter results, reiterated guidance for 2026, an accelerated peak-demand outlook in Houston, and a larger 10-year capital plan. Favorable U.S. Treasury guidance on the Corporate Alternative Mini…
Mizuho trimmed its 12-month price target for SolarEdge Technologies (SEDG) to $32 from $33 while keeping a Neutral stance. The cut reflects a weaker expected contribution from Europe and higher operating expenses, partially offset by recent gross margin gains. SolarEdge recently beat fourth-quarter sales and margin expectations and issued first-qua…
Jefferies revisited its application software coverage after sizeable underperformance across the group and, using a new AI Risk Matrix alongside company-specific fundamentals, highlighted four stocks it prefers for the AI transition: Intuit, Procore Technologies, Atlassian and Salesforce. The firm shifted several other app names to Hold because of …
The headline chart for Continental (CTTAY) understates the company's operational momentum after a corporate separation. Adjusted for the spin-off, technicals are bullish, industry secular growth in ADAS and vehicle electrification supports higher earnings, and OTC positioning provides a favorable risk/reward for a mid-term swing trade. Entry $8.70,…
Verisk Analytics said it entered into accelerated share repurchase (ASR) agreements totaling $1.5 billion with HSBC Bank USA, N.A. and Wells Fargo Bank, N.A. The stock rose 1.5% on the news. The transactions include an initial delivery of about 7.0 million shares and are expected to settle no later than the company’s third fiscal quarter ending Sep…
UBS updated its geopolitical framework and identified a group of European oil companies it believes are well positioned to benefit if an Iran-related risk premium pushes crude prices higher. The bank sees upstream-exposed producers and certain oil services and chemicals businesses as likely near-term beneficiaries, while integrated majors with disc…
Veris Residential will be taken private in a $3.4 billion cash transaction led by an investor consortium headed by Affinius Capital in partnership with Vista Hill Partners. The $19.00 per-share offer represents a 13% premium to the most recent close and follows a strategic review supported by J.P. Morgan and Morgan Stanley.
Morgan Stanley increased its price target on PTC Therapeutics to $92 from $90 and maintained an Overweight rating after updating its financial model in the wake of the company’s fourth-quarter and full-year 2025 disclosure. The firm cited operating expense adjustments and a somewhat quicker Sephience uptake as drivers for the modest target bump, wh…
Morgan Stanley trimmed its 12-month price objective for Salesforce to $287 from $298 while retaining an Overweight rating, citing a largely steady view into calendar 2026, evidence of partner bifurcation, and ongoing Agentforce pilots. The bank's survey and modelling expect continued organic growth in remaining performance obligations and subscript…
